Both cancer cohorts consistently showed inverse association of BIM deletion polymorphism with patient age (≤35 years vs. 36–50 years vs. >50 years: 29% vs. 22% vs. 15%, P = 0.006 in consecutive cohort, and 40% vs. 23% vs. 13%, P = 0.023 in metastatic cohort). Here, BCL2L11 is linked to cancer.